eligibility_summary
Adults ≥18 with measurable MM, ECOG ≤1, contraception. Relapsed after SOC ide-cel with ≥PR, ide-cel given after ≥4 lines incl IMiD/PI/anti‑CD38. LVEF ≥40, ANC ≥1000, Plt ≥25k, Hgb ≥8, CrCl ≥30, hepatic OK. Exclude: SMM/POEMS/amyloidosis/PCL, SCT <12w or GVHD, active HBV/HCV/COVID/HIV or uncontrolled infection, major CV events/arrhythmia or QTcF>470, neuropathy ≥2 or GBS, prior anti‑BCMA bispecific, preg/breastfeeding, other trials/live vaccine <4w, unresolved ≥G2 tox, serious psych risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06138275: Open-label phase 2, single-arm consolidation study of elranatamab after idecabtagene vicleucel (ide-cel) in relapsed/refractory multiple myeloma. Intervention: Elranatamab, a subcutaneous bispecific T‑cell–engager antibody (BiTE-like) that simultaneously binds BCMA on myeloma/plasma cells and CD3 on T cells, redirecting and activating cytotoxic T cells to kill BCMA-expressing cells, given in 28‑day cycles for up to 6 months. Background therapy: Ide-cel is an autologous anti‑BCMA CAR‑T cell therapy previously received as standard of care. Targets and pathways: BCMA on malignant plasma cells, T‑cell receptor/CD3 activation, immune synapse formation, cytokine-mediated cytotoxicity, and tumor cell lysis. Objective: reduce risk of progression after CAR‑T.